01/27/2015 - 12:07pm

Symplmed Pharmaceuticals announced that the Food and Drug Administration approved Prestalia (perindopril arginine and amlodipine) tablets to treat hypertension. 

01/27/2015 - 12:01pm

Rep. Jason Chaffetz, R-Utah, last week introduced a bill that would extend to new combination drugs containing molecules already approved by the Food and Drug Administration the same five-year market exclusivity as a drug product containing an entirely new set of active ingredients.

01/27/2015 - 11:11am

Health and Human Services Secretary Sylvia Burwell announced goals and a timeline to move the Medicare program toward paying providers based on the quality of care they give patients.

 

01/26/2015 - 3:12pm

The Food and Drug Administration last week announced approval for Bexsero, a vaccine intended to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals 10 years through 25 years of age.

 

01/26/2015 - 3:09pm

The Food and Drug Administration last week approved Natpara (parathyroid horomone), which is indicated to control low blood calcium levels in patients who have hypoparathyroidism.

 

01/26/2015 - 11:59am

Purdue Pharma on Monday announced the launch of Hysingla ER (hydrocodone bitartrate) extended-release tablets CII. According to the company, the once-daily drug is the first and only hydocodone product to be recognized by the Food and Drug Administration as having properties that deter misuse and abuse via chewing, snorting and injection.

01/22/2015 - 12:44pm

The global therapeutics market for Irritable Bowel Syndrome is set to rise in value from $589.6 million in 2013 to $1.5 billion by 2023, representing a high compound annual growth rate of almost 9.9%, according to a report published Thursday by research and consulting firm GlobalData.

01/21/2015 - 3:23pm

Eisai on Tuesday announced the launch of a new savings card for Belviq (lorcaserin HCl) CIV, the most-prescribed branded FDA-approved prescription drug therapy for chronic weight management.

01/21/2015 - 2:52pm

The Food and Drug Administration on Wednesday announced approval for Cosentyx (secukinumab), indicated for the treatment of adults with moderate to severe plaque psoriasis.